Patents Assigned to FemmePharma
  • Patent number: 8226972
    Abstract: Drug delivery compositions which are suitable for vaginal administration for the treatment of diseases and disorders in the urogenital tract are described. The compositions may be in the form of a tablet, liquid suspension or dispersion, dried powder, topical ointment, cream, foam, suppository, or aerosol. The drug delivery compositions are administered directly to the vagina and do not require the use of a solid device. This method of administration reduces the systematic levels of the drugs.
    Type: Grant
    Filed: December 19, 2002
    Date of Patent: July 24, 2012
    Assignee: FemmePharma Holding Company, Inc.
    Inventors: Gerianne Tringali DiPiano, John A. Ziemniak, Thomas Janicki
  • Patent number: 7812010
    Abstract: Formulations for topical or local administration of drugs directly to the breast or chest to produce a regional or local effect with lower systemic drug levels than when an effective amount is administered systemically are disclosed herein. In a preferred embodiment, the drug is administered to the surface of the breast, areola, or directly to the nipple. The formulations provide increased patient comfort, increased bioavailability and relatively high blood levels in the region to be treated with a reduction of side effects compared to those administered systemically. The preferred formulations contain drugs in the form of micro or nanoparticles, which may be formed of drug alone or in combination with an excipient or carrier. The excipient or carrier may modify the release rates or enhance absorption into the affected area. The drug formulation may be in the form of a cream, lotion or foam.
    Type: Grant
    Filed: January 2, 2004
    Date of Patent: October 12, 2010
    Assignee: Femmepharma, Inc.
    Inventors: Gerianne T. DiPiano, Peter Kevin Mays, John Ziemniak
  • Patent number: 7591808
    Abstract: Vaginal or rectal applicators for the delivery of a small volume of pharmaceutical preparation, i.e. less than 1 mL are disclosed herein. The delivery of a small volume of a pharmaceutical preparation allows for the transvaginal delivery of the preparation to the region of the upper vaginal vault or rectum for the treatment of diseases and disorders of the female urogenital system, cervix, uterus, ovaries, fallopian tubes and peritoneal cavity and the lower abdomen. The vaginal or rectal applicators contain four main parts, an applicator barrel, a plunger, a plunger tip, and an applicator cap. The applicator functions similar to a syringe. The applicator is filled with a pharmaceutical preparation with the plunger in the back position. The cap is attached to seal the pharmaceutical preparation in the applicator. To use the applicator, the cap is removed, the applicator is positioned, and the plunger is depressed.
    Type: Grant
    Filed: January 16, 2004
    Date of Patent: September 22, 2009
    Assignee: FemmePharma Holding Company, Inc.
    Inventors: Gerianne Tringali DiPiano, John Andrew Ziemniak, Joel Martin Bartholomew
  • Publication number: 20040260252
    Abstract: Vaginal or rectal applicators for the delivery of a small volume of pharmaceutical preparation, i.e. less than 1 mL are disclosed herein. The delivery of a small volume of a pharmaceutical preparation allows for the transvaginal delivery of the preparation to the region of the upper vaginal vault or rectum for the treatment of diseases and disorders of the female urogenital system, cervix, uterus, ovaries, fallopian tubes and peritoneal cavity and the lower abdomen. The vaginal or rectal applicators contain four main parts, an applicator barrel, a plunger, a plunger tip, and an applicator cap. The applicator functions similar to a syringe. The applicator is filled with a pharmaceutical preparation with the plunger in the back position. The cap is attached to seal the pharmaceutical preparation in the applicator. To use the applicator, the cap is removed, the applicator is positioned, and the plunger is depressed.
    Type: Application
    Filed: January 16, 2004
    Publication date: December 23, 2004
    Applicant: FemmePharma, Inc.
    Inventors: Gerianne Tringali DiPiano, John Andrew Ziemniak, Joel Martin Bartholomew
  • Patent number: 6652874
    Abstract: Formulations have been developed for regional delivery of drugs, for example, into a cavity such as the pelvic region, peritoneal region, or directly on organs of interest. Regional delivery increases comfort and bioavailability of the drug, resulting in rapid and relatively high blood levels in the regions to be treated in the substantial absence of side effects due to the high levels required for efficacy following systemic delivery. In the preferred embodiment, these formulations consist of drug micro or nanoparticles, which may be formed of drug alone or in combination with an excipient or polymeric carrier. The excipient or polymer may be used to manipulate release rates and to increase adhesion to the affected region. The drug formulation can be applied as a dried powder, a liquid suspension or dispersion, or as a topical ointment, creme, lotion, foam or suppository.
    Type: Grant
    Filed: May 16, 2002
    Date of Patent: November 25, 2003
    Assignee: FemmePharma
    Inventors: Vanaja V. Ragavan, Gerianne M. DiPiano
  • Publication number: 20030143278
    Abstract: Drug delivery compositions which are suitable for vaginal administration for the treatment of diseases and disorders in the urogenital tract are described. The compositions may be in the form of a tablet, liquid suspension or dispersion, dried powder, topical ointment, cream, foam, suppository, or aerosol.
    Type: Application
    Filed: December 19, 2002
    Publication date: July 31, 2003
    Applicant: FemmePharma, Inc.
    Inventors: Gerianne Tringali DiPiano, John A. Ziemniak, Thomas Janicki
  • Patent number: 6416778
    Abstract: Formulations have been developed for regional delivery of drugs, for example, into a cavity such as the pelvic region, peritoneal region, or directly on organs of interest. Regional delivery increases comfort and bioavailability of the drug, resulting in rapid and relatively high blood levels in the regions to be treated in the substantial absence of side effects due to the high levels required for efficacy following systemic delivery. In the preferred embodiment, these formulations consist of drug micro or nanoparticles, which may be formed of drug alone or in combination with an excipient or polymeric carrier. The excipient or polymer may be used to manipulate release rates and to increase adhesion to the affected region. The drug formulation can be applied as a dried powder, a liquid suspension or dispersion, or as a topical ointment, creme, lotion, foam or suppository.
    Type: Grant
    Filed: July 23, 1999
    Date of Patent: July 9, 2002
    Assignee: FemmePharma
    Inventors: Vanaja V. Ragavan, Gerianne M. DiPiano
  • Patent number: 5993856
    Abstract: Formulations which have been developed for topical or local delivery intrapelvically, intraperitoneally or directly on reproductive organs of interest administration to a region such as the female reproductive system, provide for increased comfort, increased bioavailability, rapid and relatively high blood levels in the regions to be treated in the substantial absence of systemic levels of drug which might cause side effects. These formulations consist of drug micro or nanoparticles, which may be formed of drug alone or in combination with an excipient or polymeric carrier. The excipient or polymer may be used to manipulate release rates and to increase adhesion to the affected region. The particulate formulation can be applied as a dried powder, a liquid suspension or dispersion, or as a topical ointment, creme, lotion, foam or suppository.
    Type: Grant
    Filed: November 17, 1997
    Date of Patent: November 30, 1999
    Assignee: FemmePharma
    Inventors: Vanaja V. Ragavan, Gerrianne M. DiPiano